Daniel R. Mudra

1.3k citations

18 papers · 647 indexed · h-index 11

Impact in

Pharmacology top 1%
- Pharmacogenetics and Drug Metabolism
- Drug-Induced Hepatotoxicity and Protection
Pharmaceutical Science top 5%
- Drug Solubulity and Delivery Systems

Papers in

Pharmacology 10
- Pharmacogenetics and Drug Metabolism 9
- Inflammatory mediators and NSAID effects 5
Pharmaceutical Science 2

Co-authors: Andrew Parkinson Ronald T. Borchardt Maciej Czerwiński Liang‐Shang Gan Yu Li Ajay Madan Kathleen Carroll Jameson Forster
Journals: Journal of Medicinal Chemistry (4 papers)Journal of Pharmaceutical Sciences (3 papers)Bioorganic & Medicinal Chemistry Letters (3 papers)ACS Medicinal Chemistry Letters (1 paper)Current Drug Metabolism (1 paper)
Partner nations: United States Spain

In The Last Decade

Daniel R. Mudra

18 papers receiving 621 citations

Peers

Countries citing papers authored by Daniel R. Mudra

Since Specialization

Citations

This map shows the geographic impact of Daniel R. Mudra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel R. Mudra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel R. Mudra more than expected).

Fields of papers citing papers by Daniel R. Mudra

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel R. Mudra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel R. Mudra. The network helps show where Daniel R. Mudra may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Daniel R. Mudra, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Daniel R. Mudra Line = papers co-authored together Daniel R. Mudra links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work
1	Translational pharmacokinetic-pharmacodynamic analysis in the pharmaceutical industry: an IQ Consortium PK-PD Discussion Group perspective Drug Discovery Today ·Harvey Wong, Tonika Bohnert, S C Bennett, Christopher R. Gibson, Cheng‐Pang Hsu, Hai⁃yang FU, Bianca M. Liederer, Lin Jing, Qiang Lü, Jerome T. Mettetal, Daniel R. Mudra, Marjoleen Nijsen, Patricia Schroeder, Edgar Schuck, Satyendra Suryawanshi, Patrick Trapa, Alice Tsai, Haiqing Wang, Fan Wu	2017	22
2	A Highly Selective Hydantoin Inhibitor of Aggrecanase-1 and Aggrecanase-2 with a Low Projected Human Dose Journal of Medicinal Chemistry ·Timothy B. Durham, Han Ru-bing, C.L. Lee, Chin Liu, Jan Tengwall, Daniel R. Mudra, Craig Swearingen, Chaohua Lin, M.G. Chambers, Kannan Thirunavukkarasu, Michael R. Wiley	2017	12
3	Translating Molecules into Medicines Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) ·David M. Bender, Daniel R. Mudra, J. S. Morrison, Shobha Bhattachar	2017	5
4	Identification and biological activity of 6-alkyl-substituted 3-methyl-pyridine-2-carbonyl amino dimethyl-benzoic acid EP4 antagonists Bioorganic & Medicinal Chemistry Letters ·María‐Jesús Blanco, Tatiana Vetman, Srinivasan Chandrasekhar, Matthew J. Fisher, Anita K. Harvey, Andrew Ellefson, M.G. Chambers, Chaohua Lin, Daniel R. Mudra, J.L. Oskins, Xu-Shan Wang, Xiaopeng Yu, Alan M. Warshawsky	2016	10
5	Novel Autotaxin Inhibitors for the Treatment of Osteoarthritis Pain: Lead Optimization via Structure-Based Drug Design ACS Medicinal Chemistry Letters ·Spencer B. Jones, Lance A. Pfeifer, Thomas J. Bleisch, Thomas J. Beauchamp, Jim D. Durbin, Valentine J. Klimkowski, Andrzej Jaśkiewicz, Christopher J. Rito, R. Srihawong, Joseph M. Gruber, Hai H. Bui, M.G. Chambers, Srinivasan Chandrasekhar, Chaohua Lin, Denis McCann, Daniel R. Mudra, J.L. Oskins, Craig Swearingen, Kannan Thirunavukkarasu, Bryan H. Norman	2016	39
6	Use of Osmotic Pumps to Establish the Pharmacokinetic–Pharmacodynamic Relationship and Define Desirable Human Performance Characteristics for Aggrecanase Inhibitors Journal of Medicinal Chemistry ·Michael R. Wiley, Timothy B. Durham, Jan Tengwall, M.G. Chambers, Chaohua Lin, Chin Liu, Han Ru-bing, Peter G. Mitchell, Daniel R. Mudra, Craig Swearingen, C.L. Lee, Jennifer Weller, Kannan Thirunavukkarasu	2016	5
7	Discovery of potent aryl-substituted 3-[(3-methylpyridine-2-carbonyl) amino]-2,4-dimethyl-benzoic acid EP4 antagonists with improved pharmacokinetic profile Bioorganic & Medicinal Chemistry Letters ·María‐Jesús Blanco, Tatiana Vetman, Srinivasan Chandrasekhar, Matthew J. Fisher, Anita K. Harvey, M.G. Chambers, Chaohua Lin, Daniel R. Mudra, J.L. Oskins, Xu-Shan Wang, Xiaopeng Yu, Alan M. Warshawsky	2015	7
8	Discovery of substituted-2,4-dimethyl-(naphthalene-4-carbonyl)amino-benzoic acid as potent and selective EP4 antagonists Bioorganic & Medicinal Chemistry Letters ·María‐Jesús Blanco, Tatiana Vetman, Srinivasan Chandrasekhar, Matthew J. Fisher, Anita K. Harvey, Daniel R. Mudra, Xu-Shan Wang, Xiaopeng Yu, Donsuk Lee, Alan M. Warshawsky	2015	5
9	Discovery of a Novel Series of Orally Active Nociceptin/Orphanin FQ (NOP) Receptor Antagonists Based on a Dihydrospiro(piperidine-4,7′-thieno[2,3-c]pyran) Scaffold Journal of Medicinal Chemistry ·Miguel A. Toledo, Concepción Pedregal, 김교신, Nuria Cirauqui, A. MARTINEZ‐GRAU, Alma Jiménez, 뺤꽑, Alicia Torrado, Carlos Mateos, Elizabeth Joshi, Steven D. Kahl, Karen Rash, Daniel R. Mudra, Vanessa Barth, David B. Shaw, David L. McKinzie, Jeffrey M. Witkin, Michael A. Statnick	2014	49
10	Development of LC-MS/MS-Based Receptor Occupancy Tracers and Positron Emission Tomography Radioligands for the Nociceptin/Orphanin FQ (NOP) Receptor Journal of Medicinal Chemistry ·Concepción Pedregal, Elizabeth Joshi, Miguel A. Toledo, 김교신, Nuria Cirauqui, A. MARTINEZ‐GRAU, Alma Jiménez, 뺤꽑, Antonio Navarro, Zhaogen Chen, Daniel R. Mudra, Steven D. Kahl, Karen Rash, Michael A. Statnick, Vanessa Barth	2012	23
11	In Silico, In Vitro and In Situ Models to Assess Interplay Between CYP3A and P-gp Current Drug Metabolism ·Daniel R. Mudra, Kelly E. Desino, Prashant Desai	2011	28
12	Absorption Barriers in the Rat Intestinal Mucosa. 3: Effects of Polyethoxylated Solubilizing Agents on Drug Permeation and Metabolism Journal of Pharmaceutical Sciences ·Daniel R. Mudra, Ronald T. Borchardt	2009	50
13	Absorption Barriers in the Rat Intestinal Mucosa: 2. Application of Physiologically Based Mathematical Models to Quantify Mechanisms of Drug Permeation and Metabolism Journal of Pharmaceutical Sciences ·Daniel R. Mudra, Jin Y. Jin, Ronald T. Borchardt	2009	9
14	Absorption Barriers in the Rat Intestinal Mucosa: 1. Application of an In Situ Perfusion Model to Simultaneously Assess Drug Permeation and Metabolism Journal of Pharmaceutical Sciences ·Daniel R. Mudra, Ronald T. Borchardt	2009	17
15	The effect of fenbuconazole on cell proliferation and enzyme induction in the liver of female CD1 mice Toxicology and Applied Pharmacology ·Daland R. Juberg, Daniel R. Mudra, G A Hazelton, Andrew Parkinson	2006	59
16	Effects of Prototypical Microsomal Enzyme Inducers on Cytochrome P450 Expression in Cultured Human Hepatocytes Drug Metabolism and Disposition ·Ajay Madan, Richard Graham, Kathleen Carroll, Daniel R. Mudra, В Ю Россихин, Bülent Tanör, Jörg Karcher, Maciej Czerwiński, Jameson Forster, Maria Ribadeneira, Liang‐Shang Gan, Edward L. LeCluyse, Karl Zech, Philmore Robertson, Patrick Koch, Lida Antonian, Maksut K. Kulzhanov, Yu Li, Andrew Parkinson	2003	276
17	Analysis of CYP mRNA expression by branched DNA technology Methods in enzymology on CD-ROM/Methods in enzymology ·Maciej Czerwiński, Anushka Jha, Ajay Madan, K. K. Carroll, Daniel R. Mudra, Lawrence L. Gan, Gang Luo, Andrew Parkinson	2002	10
18	Preparation of Hepatocytes Current Protocols in Toxicology ·Daniel R. Mudra, Andrew Parkinson	2001	21

About Daniel R. Mudra

Daniel R. Mudra is a scholar working on Pharmacology, Pharmacology, Pharmaceutical Science, Hepatology and Oncology, having authored 18 papers that have together received 647 indexed citations. Recurring topics across this work include Pharmacogenetics and Drug Metabolism (9 papers), Drug Transport and Resistance Mechanisms (6 papers), Inflammatory mediators and NSAID effects (5 papers), Chemical Synthesis and Analysis (4 papers), Pharmacological Effects and Toxicity Studies (2 papers), Liver physiology and pathology (2 papers), Receptor Mechanisms and Signaling (2 papers) and Organ Transplantation Techniques and Outcomes (2 papers). The work is most often cited by research in Pharmacology (270 citations), Pharmaceutical Science (65 citations), Oncology (200 citations), Biochemistry (38 citations) and Hepatology (36 citations). Daniel R. Mudra has collaborated with scholars based in United States and Spain. Frequent co-authors include Andrew Parkinson, Ronald T. Borchardt, Maciej Czerwiński, Liang‐Shang Gan, Yu Li, Ajay Madan, Kathleen Carroll, Jameson Forster, Karl Zech and Patrick Koch. Their work appears in journals such as Journal of Medicinal Chemistry, Journal of Pharmaceutical Sciences, Bioorganic & Medicinal Chemistry Letters, ACS Medicinal Chemistry Letters and Current Drug Metabolism.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact